Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large drop in short interest in January. As of January 30th, there was short interest totaling 1,603 shares, a drop of 36.9% from the January 15th total of 2,541 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 22,976 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 22,976 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

Analysts Set New Price Targets

BOLT has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. HC Wainwright set a $7.00 target price on shares of Bolt Biotherapeutics and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $34.00.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BOLT. Squarepoint Ops LLC grew its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares during the last quarter. Shay Capital LLC acquired a new stake in Bolt Biotherapeutics during the 3rd quarter worth about $85,000. Susquehanna International Group LLP purchased a new stake in Bolt Biotherapeutics during the 3rd quarter valued at about $89,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $112,000. Finally, T3 Companies LLC acquired a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $208,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Trading Up 0.6%

Shares of NASDAQ:BOLT opened at $4.95 on Friday. The business’s 50-day moving average is $5.75 and its 200 day moving average is $5.48. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $10.50. The firm has a market capitalization of $9.50 million, a P/E ratio of -0.22 and a beta of 0.92.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.07) by $1.35. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $0.82 million. On average, research analysts predict that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.